Chemical Name |
Tosedostat |
CAS Number |
238750-77-1 |
MDL Number |
MFCD13185162 |
Molecular Formula |
C21H30N2O6 |
Molecular Weight |
406.47 |
Synonyms |
CHR-2797 |
Introduction of 238750-77-1 :
Tosedostat is an aminopeptidase inhibitor. IC50 & Target: Aminopeptidase[1] In Vitro: Treatment of HL-60 cells with Tosedostat (CHR-2797) leads to an increase in the secretion of Stanniocalcin 2 (STC2) protein into the growth medium. Increases in SLC7A11 expression are detectable at 60 nM Tosedostat and as early as 2 h posttreatment. The IC50s for inhibition of proliferation by Tosedostat in U-937 and HuT 78 cell lines are 10 nM and >10 μM, respectively. Tosedostat treatment increases expression of amino acid deprivation response (AADR) genes in U-937 cells but not in HuT 78 cells[1]. By 24 h with 0.01 μM Tosedostat the mean MCA production is reduced to 77.8% of the untreated control cells; similarly the MCA production is reduced to 51.3% with 1 μM, 38.5% with 5 μM, and 35.3% with 10 μM Tosedostat[2]. In Vivo: Tosedostat (CHR-2797) is active as an anticancer agent in vivo in rodent cancer models, and a dose-response relationship has been shown in two models. The effect of Tosedostat is less apparent when the tumor burden is higher before treatment[1].
Purity |
NLT 98% |
Storage |
at 20ºC 2 years |
*The above information is for reference only.